BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/7/2022 8:29:04 AM | Browse: 313 | Download: 819
 |
Received |
|
2022-03-30 13:40 |
|
Peer-Review Started |
|
2022-03-30 13:43 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-06-10 19:45 |
|
Revised |
|
2022-07-27 20:46 |
|
Second Decision |
|
2022-08-17 03:19 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-08-17 18:51 |
|
Articles in Press |
|
2022-08-17 18:51 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-08-30 20:16 |
|
Publish the Manuscript Online |
|
2022-09-07 08:29 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
All the authors report no relevant conflicts of interest for this article. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Talat Bessissow, Geoffrey C Nguyen, Osman Tarabain, Laurent Peyrin-Biroulet, Nathalie Foucault, Kevin McHugh and Joannie Ruel |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Talat Bessissow, FRCP (C), MD, MSc, Associate Professor, Department of Medicine, McGill University Health Center, 1650 Avenue Cedar, Montreal H3G 1A4, Quebec, Canada. talat.bessissow@mcgill.ca |
| Key Words |
Disease burden; Patient-reported outcome; Depressive symptoms; Ulcerative colitis; Adalimumab; Real-world data |
| Core Tip |
In real-world at week 52, over 60% of patients with moderate-to-severe ulcerative colitis treated with adalimumab had their depressive symptoms improved, as well as their quality of life, fatigue symptoms, and work impairment. No new safety signals were detected. |
| Publish Date |
2022-09-07 08:29 |
| Citation |
Bessissow T, Nguyen GC, Tarabain O, Peyrin-Biroulet L, Foucault N, McHugh K, Ruel J. Impact of adalimumab on disease burden in moderate-to-severe ulcerative colitis patients: The one-year, real-world UCanADA study. World J Gastroenterol 2022; 28(34): 5058-5075 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i34/5058.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i34.5058 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
